Articles tagged with Cancer Immunotherapy
Researchers engineered supercharged T cells that can recognize and kill prostate cancer cells more effectively. By fine-tuning how they physically interact with tumor cells, the T cells form a stronger bond, allowing them to deliver a targeted immune response without damaging healthy tissue.
Researchers at the University of Pennsylvania developed lipid nanoparticles that modify immune metabolism to strengthen mRNA vaccines and reduce common side effects. The new lipid boosts the metabolism of immune cells, providing energy for the body's defenses while dialing down inflammatory signals.
Researchers at UCLA have developed a novel immunotherapy that uses CAR-NKT cell therapy to fight endometrial cancer. The therapy achieved complete tumor elimination and prolonged survival in mouse models, outperforming conventional CAR-T cell therapies.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.
Blocking two key 'don't eat me signals' in cancer cells heightens the immune response and sensitizes tumors to immunotherapy in glioblastoma models. Researchers found that simultaneously blocking CD47 and CD24 improved immunotherapy response, allowing macrophages to better recognize and attack cancer cells.
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
Researchers have identified tyrosine phosphatase 1B (PTP1B) as a key molecular target in immunogenic cell death (ICD), a type of regulated cell death that activates the immune system against cancer cells. Two platinum-containing compounds, Pt-NHC and PlatinER, trigger ICD by blocking PTP1B's enzymatic activity.
A new study demonstrates that blocking a signaling protein called FAK helps mobilize an anti-tumor immune response, allowing tumor-fighting cells to approach tumors and shift the behavior of other immune cells to work against them. This approach achieved the best effects on immune cell recruitment, tumor size reduction, and survival ti...
The novel approach outperforms standard CAR-T cell therapy in preclinical studies using mouse models of glioblastoma and ovarian cancer. Armored CAR-T cells eliminate tumors, reshape the tumor environment, and boost immune-cell activity.
The James P. Allison Institute at UT MD Anderson Cancer Center appoints Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon to advance immunotherapy research. These experts bring expertise in immune therapy resistance, cancer vaccines, bioengineering, tumor evolution, and drug development.
Researchers analyzed 15-year data from a clinical trial, finding that 70% of patients remained alive and 42% were considered cured after treatment. Cure modeling estimated the overall cure rate at 42% of treated patients.
The Alliance for Clinical Trials in Oncology will host a webinar highlighting recent clinical advances in breast cancer, multiple myeloma, and leukemia. Researchers will present key findings from ASH and SABCS meetings, impacting treatment outcomes.
A study in Science reveals that a healthy gut microbiota enhances immunotherapy's efficacy against cancer, while antibiotics reduce diversity and may impair treatment. Analysis found specific bacterial species associated with better clinical outcomes.
The foundation awarded $400,000 over two years to five early-career researchers and continuation support to three current Innovators with significant progress on their proposed research. The recipients focus on developing targeted therapeutics, decoding dendritic cell function, defining NKT cell interactions with tumors, engineering T ...
Researchers at UCLA have found a way to supercharge immune cells with a fuel source that tumors can't steal, dramatically improving their ability to survive and attack solid tumors. The approach enables T cells to import cellobiose and convert it into usable glucose inside the cell.
Researchers found that radiation-resistant cancer cells are vulnerable to NK cell-mediated killing due to increased expression of specific cellular membrane proteins, creating an 'evolutionary double-bind'. The combination of radiation therapy and NK cell-based immunotherapy was more effective in suppressing both sensitive and resistan...
A new UCLA study found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer. The combination treatment helped patients live long enough to reach surgery, shrank tumors, and produced encouraging survival outcomes.
Researchers have engineered Listeria bacteria to stimulate the body's innate immune system and eliminate cancer cells. The therapy, which boosts gamma delta T cells, shows promise in treating children with leukemia and preventing graft-versus-host disease.
Researchers developed a PD-L1-binding antigen presenter that redirects antiviral antibodies to target cancer cells, transforming virus-specific immune memory into precision anti-cancer weapons. This strategy has significant potential for treating hard-to-treat cancers and represents a lower-cost, safer avenue for tumor immunotherapy.
Researchers have discovered a new mechanism by which an existing cancer drug can block the loss of BCMA molecules on cancer cells, allowing CAR T cell therapy to become effective again in some patients. The study shows that carfilzomib can prevent the degradation of BCMA and restore its presence on the surface of malignant plasma cells.
A new HPV cancer vaccine developed by Northwestern University scientists has shown promising results in a preclinical model. The vaccine's carefully organized structure dramatically enhances the immune system's ability to attack tumors, shrinking them and extending animal survival.
Researchers identified blood-based biomarkers that can help distinguish patients with glioblastoma who are most likely to live longer from novel treatment with an engineered oncolytic virus. The study found that adding an immune booster increased survival times and improved immunological fitness.
Researchers discovered five dominant patterns of protein-altering mutations that determine tumor visibility to the immune system. These 'fingerprints' help predict immunotherapy response and suggest a more personalized approach to cancer treatment.
A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to treat multiple solid tumors. The 4-1BB-containing CAR design emerged as superior, demonstrating strongest anti-tumor activity and persistence.
Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster and cheaper than before. This new technology enables researchers to assess which CAR T variants are most promising much more quickly, leading to safer and more targeted cancer treatments.
A recent clinical trial has shown that switching part of the standard chemotherapy protocol for a targeted immunotherapy significantly improves outcomes for young people living with acute lymphoblastic leukaemia (ALL). Nearly 89% of patients are still alive and cancer-free after three years of follow-up.
A new clinical trial shows that treating desmoplastic melanoma with immunotherapy before surgery dramatically shrinks or eliminates tumors, improving quality of life for patients. The study found that 71% of patients had no detectable cancer remaining at the time of surgery.
Lipid droplets regulate diverse cellular processes in cancer, including membrane biosynthesis and metabolic homeostasis. Targeting lipid metabolism may disrupt tumor survival and counteract immune cell-mediated protumorigenic effects.
Researchers identified statins as a potential booster for cancer immunotherapy by preventing the release of PD-L1-containing sEVs. Statin treatment suppressed UBL3 modification, reduced PD-L1 sorting into sEVs, and improved survival outcomes in lung cancer patients.
The phase III PATINA study demonstrated that adding CDK4/6 inhibitor palbociclib to standard maintenance therapy significantly prolongs progression-free survival by more than 15 months compared to standard therapy alone. The study found a meaningful improvement in median PFS with no new signals.
Five IIT researchers receive Proof-of-Concept grants to develop innovative health technologies, including a smart microscope and edible pills. These projects aim to tackle cancer, dyslexia, and diagnostics with cutting-edge technologies like quantum computing and near-infrared photonic chips.
A new Phase II trial will examine whether giving chemotherapy or chemotherapy combined with immunotherapy before surgery can improve survival compared to surgery alone. The trial aims to identify a treatment that will help patients live longer without the cancer returning.
The University of Texas MD Anderson Cancer Center has made significant advancements in cancer care through its collaborative efforts between clinicians and scientists. These breakthroughs include an immune-targeting vaccine that shows promise in intercepting cancer in patients with Lynch Syndrome, a novel immunotherapy that demonstrate...
Scientists have developed a novel immunotherapy approach that targets tumor macrophages, converting them from immune suppressors to killers. The therapy, using engineered CAR T cells, has shown promising results in preclinical models of metastatic ovarian and lung cancer.
A new blood test has been developed to predict which patients with lung cancer will benefit from the newly approved immunotherapy drug tarlatamab. The test, based on circulating tumor cells, correctly identified 85% of patients who responded to the drug and 100% of those who did not.
Researchers at Umea University have discovered a bacterial toxin, MakA, that can inhibit colorectal cancer growth without causing damage to the body. The substance changes the immune microenvironment in tumors and boosts the immune system's ability to fight cancer.
A new study suggests that durvalumab may offer a promising treatment option for limited-stage small cell lung cancer patients, extending overall and progression-free survival. However, the therapy's high cost poses significant challenges to sustainability and access in the real-world setting.
Researchers develop CAR T cell therapy that recognizes BCMA and BAFF-R proteins, providing a new approach to treating multiple myeloma. The treatment has shown promise in preclinical trials, with the potential to prevent relapse and extend lifespan.
The collaboration aims to address bottlenecks in solid tumor manufacturing and accelerate advancement into clinical trials. City of Hope's investigational gene-modified CAR T cell therapy targeting glioblastoma will be evaluated using Cellares' automated manufacturing platform and quality control system.
Researchers have developed a new way to boost the immune system's response to cancer by using specially engineered antibodies. The antibodies work by clustering multiple immune cell receptors, amplifying the signal that tells T cells to attack cancer cells.
A new study reveals that Cornell prime dots, ultrasmall fluorescent particles, can reprogram the tumor microenvironment to make it more responsive to treatment. The nanoparticles induce anti-tumor effects by stimulating innate immune responses and reprogramming key immune cells.
Two studies found that elevated bacteria levels in tumors weaken immune response, driving resistance to immunotherapy. Researchers are now exploring how to identify patients most likely to benefit from immunotherapy and develop targeted interventions to restore its effectiveness.
Researchers at MD Anderson Cancer Center have found that inhibiting GFER, a mitochondrial enzyme, in combination with immune checkpoint blockade improves antitumor response in preclinical models. This two-pronged approach holds promise for patients with pancreatic cancer.
Proton therapy has been shown to provide a significant survival benefit for patients with head and neck cancers. In another study, researchers have identified a promising target for treating pancreatic cancer by inhibiting the mitochondrial enzyme GFER. Additionally, diagnostic breast MRI may be unnecessary for some patients with early...
Researchers at EPFL have developed two bioengineering approaches that exploit extracellular vesicles to train dendritic cells to identify cancer cells without the need for tumor material. The approaches, published in Nature Communications and Science Translational Medicine, show promising results in enhancing cancer immunotherapy.
Researchers from MIT and Broad Institute develop temporary 'factory' in the liver to generate T-cell-stimulating signals, boosting immune response to vaccination and cancer immunotherapy treatments. Aged mice showed significant increases in T cell population size and function after treatment.
Researchers developed a new way to stimulate the immune system to attack tumor cells by blocking an immune checkpoint. They created multifunctional molecules called AbLecs, which combine a lectin with a tumor-targeting antibody, and showed they could boost the immune response to cancer cells.
A large-scale study identified risk factors and clinical features of ICI-ITP, a rare but serious complication of anti-cancer immunotherapy. The study found that patients with ICI-ITP tend to have lower platelet counts at the start of treatment, experience additional immune-related adverse events, and have a higher risk of death.
The study found that the investigational vaccine produced an immune response in 74% of participants and was safe and well-tolerated. A Phase 2 study is planned to evaluate the vaccine's efficacy, offering new hope for triple-negative breast cancer treatment.
Researchers at USC's Keck School of Medicine have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer. The engineered CAR T cells may offer a way to more safely treat blood cancers and reduce the chance of relapse.
Researchers found that CAR T cell therapy side effects, such as neurotoxicity and intestinal inflammation, are linked to high rates of death unrelated to cancer relapse. CirAEs were more common in patients who received cilta-cel and had higher non-relapse mortality rates.
Researchers found that patients who received immunochemotherapy before 3:00 pm experienced significantly longer progression-free survival and overall survival compared to those treated later. Earlier administration of immunotherapy was also associated with lower risks of cancer progression and death.
The ESMO Immuno-Oncology Congress 2025 will discuss key developments in immuno-oncology, including combined approaches, AI in cancer therapy, and innovative strategies across various cancers. The congress aims to advance the field of immunotherapy and improve patient outcomes.
A new study developed an antibody that blocks several ways TNBC cells survive, grow, and evade the immune system. The antibody suppressed primary tumor growth and reenergized cancer-fighting immune cells, including T-cells and macrophages, in preclinical models.
Researchers at CU Anschutz have discovered a novel therapy combination to offer new hope to ovarian cancer patients who do not respond to existing treatments. The combination of a PARP inhibitor and SM08502 boosts the effectiveness of treatment, even for patients resistant to PARP inhibitors.
Researchers at MD Anderson have made significant discoveries in the treatment of rare bile duct cancers, with zanidatamab showing promising results. Additionally, a study identified RASH3D19 as a target to overcome treatment resistance in KRAS-mutant cancers.
Researchers have discovered that rhesus macaques shed TIGIT from immune cell surfaces when exposed to plasmin, a natural enzyme involved in blood clot breakdown. This creates a soluble form of TIGIT that can still bind anti-TIGIT monoclonal antibodies, potentially leading to misleading safety and efficacy data for human trials.
A new study found that patients with advanced basal cell carcinoma may benefit from receiving immunotherapy earlier, with a significant increase in objective response rate. Researchers explored adding relatlimab to nivolumab and saw promising results in overcoming resistance to single-agent anti-PD-1.